Lifespan extension therapy:  Amorphastilbol increases life span via up-regulation of its target gene BubR1, 13/November/2017, 12.45 am

Natural product-derived therapy for anxiety and depression:  Cucurbitacin, isolated from Watermelon, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 13/November/2017, 12.17 am
November 12, 2017
Cardiac rejuvenation therapy: A therapeutic mix encompassing  Victoza and Atorvastatin (VA) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, and extends life span via up regulation of its target gene, 13/November/2017, 11.35 pm
November 13, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Lifespan extension therapy:  Amorphastilbol increases life span via up-regulation of its target gene BubR1


What is known? 

Amorphastilbol has been shown to possess anti-hyperglycemic property. However, the exact mechanism of action is far from clear.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Amorphastilbolby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

Figure 1. A therapeutic mix encompassing Amorphization may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinas

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing Amorphastilbol or its analogues, either alone or in combination with other drugs may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing Amorphization increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy:  Amorphastilbol increases life span via up-regulation of its target gene BubR1, 13/November/2017, 12.45 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.